A total of 14 published articles (15 eligible studies) and our study were included in this comprehensive meta-analysis to further evaluate the association of FCGR2A and FCGR3A polymorphisms with clinical outcome in advanced CRC patients undergoing anti-EGFR mAb based therapy [18–31]. Here, FCGR3A is linked to colorectal carcinoma.